R87.610 - Atypical squamous cells of undetermined significance on cytologic smear of cervix (ASC-US)
|Short Description:||Atyp squam cell of undet signfc cyto smr crvx (ASC-US)|
|Long Description:||Atypical squamous cells of undetermined significance on cytologic smear of cervix (ASC-US)|
|Status:||Valid for Submission|
R87.610 is a billable ICD-10 code used to specify a medical diagnosis of atypical squamous cells of undetermined significance on cytologic smear of cervix (asc-us). The code is valid during the fiscal year 2023 from October 01, 2022 through September 30, 2023 for the submission of HIPAA-covered transactions.
This code is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The code is commonly used in ob/gyn medical specialties to specify clinical concepts such as abnormal female genital cytology.
According to ICD-10-CM guidelines this code should not to be used as a principal diagnosis code when a related definitive diagnosis has been established.
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Abnormal cervical Papanicolaou smear
- Atypical squamous cells of undetermined significance on cervical Papanicolaou smear
Index to Diseases and Injuries References
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for this diagnosis code are found in the injuries and diseases index:
- - Abnormal, abnormality, abnormalities - See Also: Anomaly;
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
- Diagnoses for females only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to FEMALES only .
Convert to ICD-9 Code
|Source ICD-10 Code||Target ICD-9 Code|
|R87.610||795.01 - Pap smear (ASC-US)|
Cervical Cancer Screening
The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cancer screening is looking for cancer before you have any symptoms. Cancer found early may be easier to treat.
Cervical cancer screening is usually part of a woman's health checkup. There are two types of tests: the Pap test and the HPV test. For both, the doctor or nurse collects cells from the surface of the cervix. With the Pap test, the lab checks the sample for cancer cells or abnormal cells that could become cancer later. With the HPV test, the lab checks for HPV infection. HPV is a virus that spreads through sexual contact. It can sometimes lead to cancer. If your screening tests are abnormal, your doctor may do more tests, such as a biopsy.
Cervical cancer screening has risks. The results can sometimes be wrong, and you may have unnecessary follow-up tests. There are also benefits. Screening has been shown to decrease the number of deaths from cervical cancer. You and your doctor should discuss your risk for cervical cancer, the pros and cons of the screening tests, at what age to start being screened, and how often to be screened.
[Learn More in MedlinePlus]
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)